Abstract
The major limitation to long-term survival of lung transplant recipients remains Obliterative Bronchiolitis (OB). This entity is characterised by airway neutrophilia, inflammation and remodelling, with subsequent fibroproliferation and obliteration of small airways that ultimately results in patient death. Statins have shown potential anti-inflammatory effects and have been demonstrated to confer a survival advantage in lung transplant patients. We postulated that the beneficial effects of simvastatin in lung transplantation are at least in part due to inhibition of the epithelial production of key mediators of neutrophil chemotaxis, inflammation and airway remodelling.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
